Literature DB >> 19428832

Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection.

Xiang Gao1, Kun Cai, Jing Shi, Hao Liu, Xiaojun Hou, Wei Tu, Le Xiao, Qin Wang, Hui Wang.   

Abstract

Shiga toxin type 1 and 2 produced by Enterohemorrhagic Escherichia coli (EHEC) O157:H7 are responsible for hemolytic uremic syndrome, a life-threatening sequela. We constructed a novel fusion protein carrying both of the immunogenic B subunits derived from the two toxins, designated Stx2B-Stx1B (2S for short), expressed in the E. coli BL21 and harvested the purified protein by a simple anion-exchange chromatography method. The fusion protein induced high level humoral IgG in mice, subclass analysis showed IgG1 dominate the IgG increase trend, which indicated that a partial to Th2 response contributed to this humoral reactivity. High level neutralizing antibodies elicited by this fusion protein inhibited cytotoxicity of toxins and protected mice from lethal dose challenge of lysed EHEC O157:H7.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428832     DOI: 10.1016/j.vaccine.2009.01.115

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Analyzing of expression of novel polypeptide complexes consisting of Shiga toxin B subunit and Adherence Fimbriae of Escherichia coli based on in silico modeling.

Authors:  Zeinab Noroozian; Mana Oloomi; Saeid Bouzari
Journal:  J Mol Model       Date:  2012-04-24       Impact factor: 1.810

Review 2.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

3.  Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7.

Authors:  Víctor A García-Angulo; Anjana Kalita; Mridul Kalita; Luis Lozano; Alfredo G Torres
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

Review 4.  Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection.

Authors:  Krystle L Mohawk; Alison D O'Brien
Journal:  J Biomed Biotechnol       Date:  2011-01-03

5.  Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7.

Authors:  Kun Cai; Wei Tu; Yuenan Liu; Tao Li; Hui Wang
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

6.  A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo.

Authors:  Tao Li; Wei Tu; Yuenan Liu; Peng Zhou; Kun Cai; Zhan Li; Xiong Liu; Nianzhi Ning; Jie Huang; Shenghan Wang; Jian Huang; Hui Wang
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

7.  Oral Immunization with Recombinant Lactobacillus acidophilus Expressing espA-Tir-M Confers Protection against Enterohemorrhagic Escherichia coli O157:H7 Challenge in Mice.

Authors:  Ruqin Lin; Yiduo Zhang; Beiguo Long; Yawen Li; Yuhua Wu; Siqin Duan; Bo Zhu; Xianbo Wu; Hongying Fan
Journal:  Front Microbiol       Date:  2017-03-15       Impact factor: 5.640

Review 8.  Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing Escherichia coli.

Authors:  Su-Bin Hwang; Ramachandran Chelliah; Ji Eun Kang; Momna Rubab; Eric Banan-MwineDaliri; Fazle Elahi; Deog-Hwan Oh
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

9.  Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.

Authors:  Diana Karpman
Journal:  Nephrol Dial Transplant       Date:  2012-10       Impact factor: 5.992

Review 10.  Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development.

Authors:  Maricarmen Rojas-Lopez; Ricardo Monterio; Mariagrazia Pizza; Mickaël Desvaux; Roberto Rosini
Journal:  Front Microbiol       Date:  2018-03-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.